BioPharmSignal logoBioPharmSignal

Biotech News

AngioDynamics and The PERT Consortium® Launch Investigator-Led Research Fund to Advance Pulmonary Embolism Care

AngioDynamics (ANGO)AngioDynamicsCommercial

The ALPHA-PE Research Fund Supports Independent, Physician-Led Studies to Advance Real-World PE Evidence LATHAM, N.Y. --(BUSINESS WIRE)--Feb. 5, 2026-- AngioDynamics, Inc. (NASDAQ: ANGO), a leading and transformative medical technology company focused on restoring healthy blood flow in the body’s

Related news

ANGOAngioDynamics2026-07-14 10:00 EST

AngioDynamics Reports Record Fiscal Year 2026 Fourth Quarter and Full Year Financial Results; Continued Execution Drives Med Tech Growth and Full-Year Profitability

ANGOAngioDynamics2026-06-30 12:00 EST

AngioDynamics to Report Fiscal 2026 Fourth Quarter and Full-Year Financial Results on July 14, 2026

TEVATeva Pharmaceutical Industries2026-06-04 12:30 EST

Teva Expands European biosimilars portfolio with launch of AHZANTIVE® (aflibercept) biosimilar to Eylea®

REPLReplimune Group2026-08-19 20:01 EST

Replimune Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

IARTIntegra LifeSciences2026-06-23 12:00 EST

Integra LifeSciences Announces Key Executive Appointments

GERNGeron2026-08-18 20:01 EST

Geron Corporation Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

GERNGeron2026-07-14 20:26 EST

Geron Corporation Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

EHCEncompass Health Corporation2026-07-23 12:00 EST

Encompass Health increases and declares dividend on common stock

IARTIntegra LifeSciences2026-06-15 12:30 EST

Integra LifeSciences to Present at the 2026 Truist Securities MedTech Conference

View all latest news

AngioDynamics

Vascular and Interventional Technology AngioDynamics develops medical technologies that restore blood flow, remove thrombus and treat selected tumors. Its portfolio is organized around higher-growth interventional platforms and a broader medical-device business. Mechanical Thrombectomy AlphaVac and AngioVac are mechanical aspiration...

Recent company news

ANGOAngioDynamics2026-07-28 12:30 EST

AngioDynamics to Participate in Upcoming Investor Conferences

ANGOAngioDynamics2026-07-14 10:00 EST

AngioDynamics Reports Record Fiscal Year 2026 Fourth Quarter and Full Year Financial Results; Continued Execution Drives Med Tech Growth and Full-Year Profitability

ANGOAngioDynamics2026-06-30 12:00 EST

AngioDynamics to Report Fiscal 2026 Fourth Quarter and Full-Year Financial Results on July 14, 2026

ANGOAngioDynamics2026-06-17 12:30 EST

AngioDynamics Receives FDA IDE Approval for RELIEF Feasibility Study Evaluating NanoKnife IRE Platform as Minimally Invasive Treatment for Benign Prostatic Hyperplasia (BPH)

ANGOAngioDynamics2026-05-28 17:25 EST

AngioDynamics Expands Patient Access to NanoKnife IRE for Prostate and Liver Cancer as Medicare Coverage Framework Takes Effect

Stock data

Close
15.75 USD
Market cap
453.68M USD
Exchange
NASDAQ
Sector
MedTech
Location
United States